Tovoli, Francesco <br/><br/>
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.  [electronic resource] 

 -  Journal of hepatology  12 2019 
 - 1175-1183 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1600-0641 
<br/><br/><label>Standard No.: </label>10.1016/j.jhep.2019.08.015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--administration & dosage<br/>Carcinoma, Hepatocellular--drug therapy<br/>Dose-Response Relationship, Drug<br/>Drug-Related Side Effects and Adverse Reactions--etiology<br/>Duration of Therapy<br/>Female<br/>Humans<br/>Italy--epidemiology<br/>Learning Curve<br/>Liver Neoplasms--drug therapy<br/>Male<br/>Medication Therapy Management--statistics & numerical data<br/>Middle Aged<br/>No-Observed-Adverse-Effect Level<br/>Off-Label Use<br/>Practice Patterns, Physicians'<br/>Sorafenib--administration & dosage<br/>Survival Analysis